Pantethine for psoriasis shows promise in early research

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Pantethine for psoriasis may offer a new adjunct therapy, according to research from China that found the vitamin B5–derived supplement tempered immune activity in mice and improved symptoms in a small human study.

The findings, published October 27 in the Journal of Experimental Medicine, point to an unexpected link between cholesterol synthesis and immune regulation. By disrupting this metabolic pathway, pantethine appeared to dial back the excessive immune response that drives psoriasis and could hold relevance for other autoimmune disorders, according to the study team.

Pantethine for psoriasis and overactive dendritic cells

Central to the work are dendritic cells, immune sentinels that coordinate defenses by presenting antigens to T cells and releasing signaling molecules that recruit other immune cells and spark inflammation. While essential for protection against pathogens, dendritic cells can fuel chronic inflammation and autoimmune disease when hyperactivated.

“Emerging evidence highlights that metabolic pathways and their associated metabolites play vital roles in regulating immune cell function and autoimmune progression,” said Wei-Na Zhang of the State Key Laboratory of Biomedical Analysis in Beijing. Zhang led the research with colleagues Qing Xia, Ai-Ling Li, Tao Zhou, and Cheng-Xin Li of The First Medical Center of Chinese PLA General Hospital.

Hidden link between cholesterol metabolism and immune activation

The researchers detected elevated levels of enzymes known as Vanins in dendritic cells from people with psoriasis and several other autoimmune conditions. Lowering Vanin expression made dendritic cells less active and less able to stimulate T cells, and a Vanin inhibitor prevented psoriasis from developing in mice, the team reported.

Vanins convert pantethine into vitamin B5, a nutrient required for cellular energy production. Pantethine is available as a dietary supplement and is commonly used to help reduce blood cholesterol by curbing its synthesis. Cholesterol also shapes immune cell behavior. Prior studies have shown cholesterol can enhance dendritic cell activity, and high blood cholesterol is a known risk factor for psoriasis.

The team found that excessive Vanin activity depleted intracellular pantethine in dendritic cells. As pantethine dropped, cholesterol production rose, and dendritic cells became abnormally active. Restoring pantethine reversed this pattern by limiting cholesterol buildup in dendritic cells and suppressing inflammatory overactivation.

“We found that pantethine administration effectively alleviated psoriasis in mice, suggesting that insufficient pantethine levels may be the crucial contributor to hyperactivation of dendritic cells and autoimmune inflammation following the up-regulation of Vanins,” Zhang said.

Small human study tests pantethine for psoriasis

Building on laboratory and animal data, the investigators ran a pilot clinical study with 24 adults with psoriasis. All participants used a topical calcipotriene/betamethasone combination, a standard therapy that regulates skin cell growth and reduces inflammation. Half also received pantethine tablets to evaluate whether the supplement could enhance routine care.

After 12 weeks, patients who took pantethine alongside the ointment had greater symptom improvement than those on topical therapy alone. The effect was most notable among participants with elevated cholesterol at baseline, the researchers reported.

The authors cautioned that the trial’s small size limits firm conclusions and that the patient outcomes do not prove the same cellular mechanism observed in the laboratory. Larger, controlled studies are needed to confirm efficacy and clarify how the supplement exerts its effects in people.

“Our investigator-initiated clinical trial demonstrated encouraging therapeutic efficacy of pantethine as an adjunctive therapy in psoriasis, but these findings should be interpreted as proof-of-concept for clinical feasibility rather than direct mechanistic validation,” Zhang said. The team described a “Vanin–pantethine–cholesterol axis” as a key metabolic pathway regulating dendritic cell activation and a potential target for therapies across dendritic cell–mediated autoimmune diseases. Related work on emerging biomedical interventions includes research into how gene editing could curb lifelong meds, but at a cost.

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp